Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

Huinan Jiang, Xianming He, Qing Leng, Miao Miao, Ming Zhang, Yingchun Li, Guojun Zhang, Jia Li, Rong Zhang, Ying Lv, Zhuogang Liu, Fei Tian, Rong Li, Wenxia Liu, Rui Zhang, Xiaohong Wang, Aijun Liao

Blood (2024) 144 (Supplement 1): 7081.

https://doi.org/10.1182/blood-2024-201906

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Luo, Jonathan How, John M. Storring, Gizelle Popradi

Blood (2024) 144 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2024-198536

Published: 2024

Journal Articles

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Yuqin Song, Ningjing Lin, Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinna Ma, Miao Hu, Yanping Zhang, Jia Li, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2024-200544

Published: 2024

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

Exploration of Rituximab Plus Lenalidomide（R 2 ）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy

Jia Li, Ou Bai, Yangzhi Zhao, Wei Guo, Xingtong Wang

Blood (2024) 144 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2024-204951

Published: 2024

Journal Articles

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Agnish Dey, Jia Li, Jae H. Park, Leopold Sellner, Varsha Sundaresan, Maria Lia Palomba, Jorge Mansilla-Soto, Brigitte Senechal, Xiuyan Wang, Devanjan S Sikder, Ajeeta Dash, Isabelle Riviere, Michel Sadelain, Ganesh Mugundu

Blood (2024) 144 (Supplement 1): 7138.

https://doi.org/10.1182/blood-2024-203375

Published: 2024

Journal Articles

The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma

Xingtong Wang, Wei Guo, Yangzhi Zhao, Jia Li, Ou Bai

Blood (2024) 144 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2024-206302

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Ying Zhang, Wei Guo, Yangzhi Zhao, Zhumei Zhan, Haotian Wang, Zhe Li, Bowen Wang, Luming Cao, Xin Wan, Jia Li, Ou Bai

Blood (2024) 144 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2024-204677

Published: 2024

Journal Articles

Lenalidomide in Combination with Etoposide Induced Ferroptotic Cell Death in DLBCL

Jia Li, Wei Guo, Yangzhi Zhao, Xingtong Wang, Xin Wan, Ou Bai

Blood (2023) 142 (Supplement 1): 5788.

https://doi.org/10.1182/blood-2023-186912

Published: 2023

Journal Articles

The Combination of Pegfilgrastim and Filgrastim Improves the Outcomes of Mobilization and Engraftment after Transplantation of Autologous Hematopoietic Stem Cells for the Treatment of Lymphoma

Xingtong Wang, Wei Guo, Yangzhi Zhao, Jia Li, Xin Wan, Ou Bai

Blood (2023) 142 (Supplement 1): 4891.

https://doi.org/10.1182/blood-2023-182840

Published: 2023

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Journal Articles

A Retrospective Analysis on the Efficacy and Saftey of Obinutuzumab in the Treatment of Non-Hodgkin B Cell Lymphoma

Yangzhi Zhao, Wei Guo, Jia Li, Xingtong Wang, Xin Wan, Junna Li, Ou Bai

Blood (2023) 142 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2023-187801

Published: 2023

Journal Articles

A Multicenter, Prospective Clinical Study of the R-CDOP Regimen in Previously Untreated Non-Hodgkin Lymphoma with High Tumor Burden

Wei Guo, Xingtong Wang, Yangzhi Zhao, Jia Li, Chunshui Liu, Xin Wan, Ou Bai

Blood (2023) 142 (Supplement 1): 1736.

https://doi.org/10.1182/blood-2023-188580

Published: 2023

Journal Articles

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Zahra Mahmoudjafari, Jia Li, Eric Bercaw, Hélène Parisé, Katalin Bognar, Si-Tien Wang, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 7246.

https://doi.org/10.1182/blood-2023-174218

Published: 2023

Journal Articles

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Zahra Mahmoudjafari, Danilo Di Maio, Jia Li, Katherine L. Rosettie, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 3703.

https://doi.org/10.1182/blood-2023-174918

Published: 2023

Journal Articles

CRM1/XPO1-FOXO1 Pathway Is Associated with Clinical Outcome and Represents a Promising Target in B-Cell Acute Lymphocytic Leukemia

Shiyu Deng, Jiawang Ou, Cai Zihong, Zicong Huang, Jia Li, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2023-188459

Published: 2023

Journal Articles

TET2-Mediated Dysregulation of Heterochromatin in Age-Related Clonal Hematopoiesis

Tingting Hong, Jia Li, Lei Guo, Maryn Cavalier, Tianlu Wang, Shaohai Fang, Anna Guzman, Katharina Wohlan, Chiraag Kapadia, Yaling Yang, C. Cameron Yin, Shaoying Li, M. James You, Xiaodong Cheng, Yubin Zhou, Margaret Goodell, Yun Nancy Huang

Blood (2023) 142 (Supplement 1): 5606.

https://doi.org/10.1182/blood-2023-178792

Published: 2023

Journal Articles

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Justin Gatwood, Anthony Masaquel, Ryan Ross, Danny Sheinson, Farah Hossain, Jia Li, Cameron James, David Fox

Blood (2022) 140 (Supplement 1): 7906–7907.

https://doi.org/10.1182/blood-2022-157905

Published: 2022

Journal Articles

The Short-Term Efficacy and Safety of Obinutuzumab Plus Chemotherapy in B-NHL with High Tumor Burden: A Real-World, Retrospective Study

Xin Wan, Wei Guo, Xingtong Wang, Yangzhi Zhao, Jia Li, Junna Li, Zhumei Zhan, Ou Bai

Blood (2022) 140 (Supplement 1): 11977–11978.

https://doi.org/10.1182/blood-2022-169343

Published: 2022

NARROW

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Exploration of Rituximab Plus Lenalidomide（R 2 ）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Lenalidomide in Combination with Etoposide Induced Ferroptotic Cell Death in DLBCL

The Combination of Pegfilgrastim and Filgrastim Improves the Outcomes of Mobilization and Engraftment after Transplantation of Autologous Hematopoietic Stem Cells for the Treatment of Lymphoma

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Retrospective Analysis on the Efficacy and Saftey of Obinutuzumab in the Treatment of Non-Hodgkin B Cell Lymphoma

A Multicenter, Prospective Clinical Study of the R-CDOP Regimen in Previously Untreated Non-Hodgkin Lymphoma with High Tumor Burden

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

CRM1/XPO1-FOXO1 Pathway Is Associated with Clinical Outcome and Represents a Promising Target in B-Cell Acute Lymphocytic Leukemia

TET2-Mediated Dysregulation of Heterochromatin in Age-Related Clonal Hematopoiesis

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

The Short-Term Efficacy and Safety of Obinutuzumab Plus Chemotherapy in B-NHL with High Tumor Burden: A Real-World, Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only